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Abstract 
Background: The pathogenesis of Graves’ ophthalmopathy (GO) and the mechanisms 
for its link to thyroid autoimmunity are poorly understood. Our present research focuses on 
the role of the skeletal muscle calcium binding protein calsequestrin (CASQ1). Earlier studies 
from our group (1) showed that the CASQ1 gene was up regulated in thyroid tissue from 
patients with GO compared to those with Graves’ hyperthyroidism (GH) without eye signs, 
raising the possibility that the orbital autoimmune reaction begins in the thyroid gland. Here, 
we measured the concentration of the CASQ1 protein in normal and Graves’ thyroid tissue, 
correlating levels with parameters of the eye signs, CASQ1 antibody levels and CASQ1 gene 
polymorphism rs3838284. 
Methods: The CASQ1 protein was measured by quantitative Western Blotting. 
Following electrophoresis, samples were transblotted to PVDF membranes, incubated with a 
1:1000 dilution of a rabbit anti-CASQ1 antibody and incubated with an HRP-conjugated goat 
anti-rabbit antibody, or anti-mouse antibodies for GAPDH. The protein concentrations were 
determined from density quantification using the Quantity One 4.4.0 ChemiDoc program and 
expressed as pmol/mg total protein by reference to CASQ1 standards. 
Results: Western blot analysis showed the presence of two forms of CASQ1 in the 
thyroid of 50 and 60 kDa molecular weight. The mean (156.71 ± 30.14 pmol/mg) 
concentration of the CASQ1 protein was significantly reduced in patients with Graves’ 
disease, with and without ophthalmopathy, compared to normal thyroid from control subjects 
with multi-nodular goitre or thyroid cancer. Although the mean was (74.5 ± 23.63 pmol/mg) 
of CASQ1 concentrations, in patients with GO it was lower than that and in compared with 
patients with GH this difference was not significant. Reduced CASQ1 in Graves’ thyroid 
correlated with the homozygous genotype of the rs3838284 CASQ1 polymorphism. 
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Conclusions: Decreased CASQ1 in the thyroid of patients with Graves’ disease compared to 
normal thyroid from control subjects is not explained but may reflect consumption of the 
protein in the course of an autoimmune reaction against CASQ1 in the thyroid. Normal 
CASQ1 protein levels in thyroid tissue from patients with toxic nodular goitre may suggests 
that this is due to the autoimmune reaction rather than the hyperthyroidism.  
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Introduction 
Graves’ disease (GD) is a heterogeneous autoimmune disorder affecting, with varying 
degree of severity, the thyroid, eyes, and skin. Graves’ ophthalmopathy (GO) is considered to 
be a chronic, autoimmune inflammatory disorder that affects all orbital tissue sections and 
results in various eye features (2). Ophthalmopathy greatly reduces the quality of life in 
affected patients and rapid worsening of GO can occur at any time. Graves’ disease can be 
seen in both sporadic and familial forms, it is well known that Graves’ disease runs in 
families and is a polygenetic and multi-factorial disorder. The sequence of events that leads to 
the development of Graves’ hyperthyroidism include: a genetic susceptibility and some 
subsequent external (environmental) stimulus such as infection, stress, or trauma. It is 
important to note that no gene has been identified that shows the genetic cause of the Graves’ 
ophthalmopathy (3). 
The pathogenesis of the ophthalmopathy and, in particular, the mechanism for its link to 
thyroid autoimmunity (Graves’ hyperthyroidism and the more common Hashimoto’s 
thyroiditis) is poorly understood. Our detailed studies over several years have shown that Abs 
against the “64 kDa proteins”, later showed to comprise flavoprotein (Fp), the ID protein, and 
the calcium binding protein calsequestrin (CASQ), were frequently detected in patients with 
ophthalmopathy. Calcium binding protein calsequestrin is responsible for muscle contraction-
relaxation, respiration and heartbeat. Calsequestrin is located in the sarcoplasmic membrane 
of the muscle fibers where it binds and releases calcium ions during either processes. CASQ 
is an acid glycoprotein located in the luminal space of the terminal cisternae of the 
sarcoplasmic reticulum, binds the calcium ion with the low affinity but high capacity and is 
believed to function as a storage protein for calcium. It is found in cardiac, skeletal and 
smooth muscle and has been isolated in several non-muscle tissues including in the 
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cerebellum and plant cells. The ‘‘skeletal’’ isoform of CASQ1 is found in fast-twitch skeletal 
muscle, while the cardiac isoform CASQ2 is expressed in the heart and in slow-twitch 
skeletal muscle. Two different genes encode the isoform, the human skeletal muscle CASQ 
gene CASQ1, located to band 1q21, and the cardiac CSQ gene CASQ2, located to bands 
1p11-p13.3, share 64% amino acid homology, however, recent studies showed that antibodies 
against CASQ1 and CASQ2 do not share epitopes as previously thought.  
Previous studies have shown that antibodies against calsequestrin-1 protein are typically 
associated with eye muscle damage in patients with Graves’ ophthalmopathy (GO) (1, 3-6). 
Calsequestrin gene has been found upregulated in the thyroid of patients with Graves’ disease 
(7), patients with thyroid autoimmunity, especially those with ophthalmopathy. These 
findings suggest that calsequestrin genetic upregulation may begin in the thyroid tissues, then, 
spreads to the eye muscles, which in some cases results in damage and loss of sight. 
A possible genetic role of calsequestrin has been raised by the results from several studies; 
Single Nucleotide Polymorphisms (SNPs) on the calsequestrin gene, for example, have been 
associated with type 2 diabetes (8-10), and noncoding SNPs in CASQ1 gene found to alter 
diabetes susceptibility (9). In this thesis study, 8 informative SNPs in calsequestrin gene were 
found.  
We also showed by quantitative western blotting that CASQ1 protein levels were reduced in 
thyroid of patients with Graves’ disease with and without ophthalmopathy compared to 
normal thyroid. 
 
Graves’ ophthalmopathy is also present in about 5-10% of patients with Hashimoto’s 
thyroiditis (11) and in patients with more subtle cases of subacute and silent  thyroiditis (12). 
Ophthalmopathy is a disorder that occurs in families and it has different causes that might 
include genetic factors, although no gene has been clearly identified.  
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Although antibodies against CASQ1 are good markers they are not specific to GO, in fact, 
they have been detected in small portions of apparently normal subjects and patients with 
skeletal muscle damage or inflammation (13).  
Calsequestrin 1 gene (CASQ1) was expressed 4.7 times more in the extra ocular muscle fibers 
than in other skeletal muscle (14) and upregulated 4.1 fold in thyroid tissues of patients with 
GO but this increase was not significant. CASQ2 gene was the most upregulated in thyroid 
tissue from patients with GO compared to those without ophthalmopathy (7). Interestingly, 
Zeiger et al., 2010 reported that calsequestrin-1 was decreased in extra-ocular muscle, and in 
this study our results shows CASQ1 is decreased in thyroid tissue.  
A possible explanation for the reduction of CASQ1 protein in thyroid tissues could be due to 
autoimmune reaction or hyperthyroidism. To distinguish between these two possibilities, it is 
necessary to measure the levels of CASQ1 in isolated multi-nodules of thyroid tissue, if the 
levels of CASQ1 are reduced in the nodules, this indicates CASQ1 protein expression is 
influenced by hyperthyroidism rather than autoimmune reaction.   
The specific interactions of calsequestrin with thyroid autoimmunity are not well understood, 
however, this study and others (13, 15), are supporting a role for CASQ1 as a molecular 
marker in Graves’ disease. 
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Chapter I: Literature Review 
- The role of the thyroid in eye disease - 
 
Thyroid 
The thyroid is one of largest endocrine glands in the human body. It has a butterfly 
shape and it is located in the neck, shielded by the cartilage that also forms the so called 
Adam’s apple. This gland consists in two endocrine components. The first produces thyroid 
hormones (T3 and T4), the second is involved in the production of calcitonin. 
Thyroid is a follicular gland that is constituted by follicular structures where the produced 
hormones are stored. Calcitonin, a small peptide of 32 amino acids, instead is produced by C 
cells, or parafollicular cells, located outside the follicles.  
The main role of the thyroid is the production of the above-mentioned hormones and 
calcitonin. The function of the gland is to control how quickly the body uses energy, makes 
proteins and how sensitive the body has to be towards other hormones. T3 and T4, 
triiodothyronine and thyroxine respectively, regulate the growth and the function of many 
other systems in the body. On the other hand, calcitonin plays a role in calcium homeostasis. 
The upstream regulation of the hormonal output from the thyroid is supervised by yet another 
hormone, the Thyroid-Stimulating Hormone (TSH), produced by the anterior pituitary, which 
in turns is regulated by Thyrotropin-Releasing Hormone (TRH) produced by the 
hypothalamus. There is therefore a continuous communication between thyroid and 
hypothalamus which in unfortunate circumstances misregulates the results in development of 
thyroid disorders. 
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Figure 1. Thyroid gland is butterfly shaped, located next to the trachea. 
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Figure 2. The hypothalamus stimulates the pituitary gland to secrete thyroid stimulating hormone, and the TSH 
stimulates the thyroid to produce thyroxin. Thyroxin has two forms, T3 and T4. T3 is the active form of the 
hormone. 
 
Thyroid Diseases description: background 
The Persian physician and philosopher, Avicenna first described the relationship between 
thyroid related eye disease and the classic swollen neck feature of this disease, called goiter, 
around AD 1000 (16). Current terminology refers to the ophthalmopathy as associated with 
Graves’ disease or Graves’ ophthalmology (GO) (17). A detailed classification of this disease 
subtypes can be defined by three groups, namely:  
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Graves’ hyperthyroidism (GH), initially results from the activation of the TSH receptors by 
TSH and TSH-receptor stimulating antibodies. However, recent hypothesis explains further 
argumentation of hyperthyroidism and thyroid ophthalmopathy as the results from increased 
levels  of CASQ1 and Col.XIII antibodies in patients serum(1).  
Thyroid-associated ophthalmopathy (TAO), which is a more general term referring to the 
swelling and inflammatory process against the extraocular muscles and orbital connective 
tissue (18), and it divides in three subgroups: ocular myopathy, congestive ophthalmopathy 
and mixed congestive and myopathic ophthalmopathy. The trigger that causes Graves’ 
disease appear to be a genetic predisposition, which plays a modest role, but also well known 
and proven environmental and endogenous factors (stress, smoking and gender) (2).  
Euthyroid Graves’ disease, which occurs in apparent absence of thyroid autoimmunity features and 
Thyroid-Stimulating Hormone receptor (TSHr) antibodries. Ophthalmopathy is also present in       
5-10% of patients with Hashimoto’s thyroiditis (11), and it is characterized by 
hypothyroidism. However the mechanism of autoimmunity that characterizes Graves’ 
hyperthyroidism and Hashimoto’s thyroiditis, are not well understood. Prominent 
characteristics features of  Thyroid eye disease (TAO) can be seen in the following figures 
(Fig. 3 and Fig. 4).  
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TAO 
 
Figure 3. Three pictures of patients with GO (from left to right): 
• Patient with inflammatory Graves’ ophthalmopathy, showing redness of the eyelids and diffuse redness 
of the conjunctiva. Edema of the eyelids is also clearly visible; 
• Patient with inflammatory Graves ophthalmopathy showing grossly enlarged caruncle and edema of the 
eyelids; 
• Patient with burnt out GO. The swelling of the eyelids is not caused by edema; 
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This woman also had limited eye mobility, lagopthalamos 
(eye cannot close completely), corneal ulcers, corneal 
punctate in the right eye that cannot be seen in this 
picture (dots or depressions),  and reduce visual activity 
in the left eye (5/10).
Woman with severe Graves’ Ophthalmopathy. Henneman, G. (2003). “Chapter 12-
Graves’ Disease; Complications.” The Thyroid and its Diseases. 
www.thyroidmanager.org/chapter12/12-text.htm. Accessed 16/10/2007
 
Figure 4. Graves’ disease complications in a subject.  
 
Subgroups and clinical features of TAO  
The three main subgroups of TAO are:  
• ocular myopathy is the most sever form of TAO. The extraocular muscle is 
functionally and structurally damaged through eye muscle autoimmune reaction, 
clinical features include diplopia, eye orbital muscle dysfunction and exophthalmos.  
• congestive ophthalmopathy leaves the eye in minimal swelling, periorbital edema, 
chemosis and/or exophthalmos state during an inflammatory process against the eyelid 
and orbital tissue.   
• mixed congestive and myopathic ophthalmopathy shows characteristics from the 
both previous subgroups (17, 18).  
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TAO affects both genders with a skewedness towards the females of 5.5 to 1 (16 women and 
9 men per year over a population of 100,000 people) (17). It is an autoimmune disease; 
however, its pathogenesis is still poorly understood.GO is often mild and self-limiting, but 
sometimes symptoms can be severe.  
To classify various forms of TAO initially NOSPECS classification was used to look at the severity of 
symptoms; however, it was not informative enough to tell about the activity of TAO, therefore, it is no 
longer in use. Mourits et al. (19) derived a Clinical activity score. Which looks at the symptoms of 
inflammation, but does not distinguish between different types of TAO and it is very subjective. 
Nunery distinguishes between TAO without restrictive myopathy (type 1) and with restrictive 
myopathy. Ocular myopathy score, the Congestive ophthalmopathy score, Upper eyelid retraction 
score, and eye assessment, looks at different types of TAO and severity and activity.  Various features 
of TAO are summarized in Table 1. 
 
 
Table 1. The most common eye signs and symptoms of the main subtypes* of thyroid-associated 
ophthalmopathy (TAO) and the serum autoantibodies detected most often. 
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Pathogenesis 
There are several different hypotheses for the cause of TAO. Thyroid-Stimulating Hormone 
receptor, calsequestrin-1 and collagen XIII proteins are candidate markers that shown to be 
associated with TAO. TSH-r is the most accepted marker by most investigators, however, in 
recent years, the last two markers have also shown good potential in several studies.  
The most accepted hypothesis for the development of TAO is the so called “TSH-r 
hypothesis”.  This model is widely accepted, however, it still remains controversial for the 
following reasons: the uncertainty is due to the presence of TSH-r in other cell types 
(fibroblasts and adipocytes), in different locations of the body, like the abdominal wall, which 
are not affected during the development of Graves’ disease (1). This controversial role of 
TSH-r as marker led to search for alternative markers associated with TAO.  Calcium binding 
protein calsequestrin-1, an internal protein found over expressed in extraocular muscle in 
patients with ophthalmopathy and collagen XIII (Col.XIII), an orbital fibroblasts’ membrane 
protein have shown to be additional markers associated with TAO.  
Studies from our research group have demonstrated significant prevalence of antibodies 
against CASQ1 and Col.XIII both in patients with Graves’ thyroiditis (20). Euthyroid graves’ 
patients are ambiguous cases where serum antibodies against CASQ1 and Col.XIII are shown 
to be positive and TSH-r antibodies are negative for the patients tested (21). These findings 
strengthen the role of genetics in the development of the ophthalmopathy. 
In addition, CASQ1 antibodies have also been detected in patients with Hashimoto’s 
thyroiditis and patients with transient thyroiditis (1). Hashimoto’s thyroiditis often leads to 
changes to the eyes and these changes have been associated with antibodies against 
calsequestrin-1 and collagen XIII. The ophthalmopathy associated with Hashimoto’s 
thyroiditis cannot be explained by the TSH-r hypothesis as antibodies against TSH-r generally 
not detected in these patients serum (11). 
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Ophthalmopathy is an autoimmune disease that has poorly understood mechanisms and a 
relation between proper markers failed to be found. Nonetheless calsequestrin-1 and collagen 
XIII have continually demonstrated to be more exhaustive markers. TSH-r hypothesis is 
summarized in Fig. 5 
 
Figure 5. Pathogenesis of Graves’ Disease and Ophthalmopathy. Ginsberg, J. (2003) ‘Diagnosis and 
management of Graves’ Disease.’ Canadian Medical Association Journal. V. 168; 575-585. 
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Causes 
While the causes of the TAO remain unclear some of the processes involved have been 
identified. The autoimmune reaction is the result of T-lymphocytes that induce B-cells to 
secrete autoantibodies against thyroid tissue and/or (it depends on how much the disorder 
develops in the patient) common orbital tissue antigens. This mechanism does not explain the 
whole process for development of ophthalmopathy because unequivocal antigens have not yet 
been associated with it. A common antigen is, as previously mentioned, TSH-r, but others 
have been identified over the past decade suggesting an important role in the autoimmunity 
reaction: G2s, fragment of FOXP1 transcription factor; the flavoprotein subunit of the 
mitochondrial succinate dehydrogenase (18); collagen XIII, found on the cell membranes of 
the orbital fibroblasts, which may be related to the periorbital inflammation of the 
ophthalmopathy, and the skeletal calcium binding protein calsequestrin, an internal protein 
attached to the sarcolemmal membrane.        
The markers listed above are shown in figure 6, which shows the reorganization of 
autoantigens in an extraocular fiber and in orbital fibroblasts. 
Calsequestrin-1 positive lymphocyte in particular have been found prevalent in all patients 
with Graves’ ophthalmopathy, in the majority of those where the disease process was ongoing 
and a portion of patients with Graves’ hyperthyroidism without ophthalmopathy (6). 
Detailed studies from our research group over many years have shown that the above markers 
were frequently detected in patients with ophthalmopathy. Collagen XIII and calsequestrin-1 
antibodies have proven to be a promising path to follow for characterization of Graves’ 
disease (6), although, this thesis will be focusing mostly on the research carried on the role of 
calsequestrin-1 protein in reference to these specific pathologies.  
24 
 
           
Figure 6. Eye muscle and orbital fibroblast autoantigens recognized by T-lymphocytes or antibodies in TAO. 
The working hypothesis is that the ocular myopathy subtype of TAO is initiated by T-lymphocyte-mediated 
targeting of calsequestrin or a yet unidentified eye muscle cell membrane antigen. Serum antibodies against 
flavoprotein and G2s are likely to be secondary to release of the proteins following muscle fiber necrosis. 
Chronic eyelid disease, which is a feature of TAO or a dominant sign in patients with Hashimoto’s thyroiditis, 
may be the result of T-lymphocyte-mediated targeting of calsequestrin in the upper eyelid levator palpebrae 
superioris muscle. The congestive ophthalmopathy subtype of TAO is likely to result from a reaction against the 
TSH-r or collagen XIII in the fibroblast cell membrane, which leads to fibroblast stimulation and excess 
production of collagen and glycosaminoglycans. The different reactions shown in the figure may occur alone or 
in combination. Reproduced with the permission from: Bednarczuk T, Gopinath B, Ploski R, Wall JR. 
Susceptibility genes in Graves' ophthalmopathy: searching for a needle in a haystack? Clin Endocrinol (Oxf). 
2007;67(1):3-19. Epub 2007/05/25.(22). Abbreviations: MCH, major histocompatibility complex; TSH-r, 
thyroid-stimulating hormone receptor. 
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- Role and function of calsequestrin-1 - 
 
Overview: role, function and localisation of calsequestrin protein  
Calsequestrin is a major Ca2+ binding protein that is present in two isoforms: 
calsequestrin-1 found in fast-twitch, skeletal muscle tissues and calsequestrin-2 specifically in 
cardiac muscle but the two isoforms can be found in several other non-muscle tissues. Its role 
is to provide necessary levels of calcium for muscle contraction-relaxation, respiration and 
heartbeat (23, 24).  
 
Calsequestrin is found in cardiac, skeletal and smooth muscle and has been isolated in several 
non-muscle tissues including in the cerebellum and plant cells. It stores calcium ions in 
sufficient quantities (up to 20 mM) to allow repetitive contractions and is essential to maintain 
movement, respiration and heartbeat. Calsequestrin is a highly acidic protein with up to 50 
calcium binding sites formed simply by the clustering of two or more acidic residues. 
Calsequestrin is 367 amino acids glycoprotein with and molecular weight of approximately 40 
kDa, however, on SDS-PAGE gel electrophoresis it appears as two bands with ~ 60, and 50 
kDa.  The monomer contains three redox inactive TRX-fold domains (Thioredoxin domain). 
When calcium binds there is a structural change whereby the alpha-helical content of the 
protein increases from 3 to 11% (25). Both forms of calsequestrin are phosphorylated by 
casein kinase II, but the cardiac form is phosphorylated more rapidly and to a higher degree. 
The human skeletal muscle CASQ gene CASQ1 has 11 exons, located to chromosom 1 band 
q21, and the cardiac CSQ gene CASQ2, located to chromosom 1 bands 1p11-p13.3, share 
68.4% amino acid homology (7), however, Abs against CASQ1 and CASQ2 do not share 
epitopes. 
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The synthesis and maturation of the protein takes place in the endoplasmic reticulum (ER) 
where, once completely formed, it is packed and protected  by a complex of chaperonin 
proteins (26) to the mitochondria and some of the CASQ protein moves and incorporated in 
the cell membrane during the assembly of the protein (27). Calsequestrin protein that migrates 
to the cell membrane interacts mainly with some abundant transmembrane protein such as: 
triadin, a 26 KDa protein, and ryanodine receptors, a class of intracellular calcium channels. 
These interactions allow calcium-induced calcium-release processes in cell tissues like muscle 
and neurons. These processes are triggered like shown in Fig. 7, by the recognition of CASQ 
by two receptors on the SR membrane, namely Ryanodine receptor and Triadin receptor. 
Calsequestrin protein carrying calcium builds up in the Lumin side of the SR membrane. The 
presence of calcium (or magnesium) on the Lumin side of the SR membrane activates the 
epitopes on the RyR2 on the membrane, this allows the calcium to be transferred from the 
Lumin side of the SR membrane to the Cytosolic side. Once the calcium crosses the RyR2 it 
inactivates it binding on a particular site of the receptor. This receptor will be reactivated 
when the empty calsequestrin protein binds to the Triadin receptor allowing it to shift to a site 
of the RyR2 giving the signal to the later receptor to open or close in relation to the needs for 
calcium ions (28). 
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Figure 7. Summary cartoon of RyR2 luminal Ca2+ regulation. Triadin is labeled TR. Calcium binding sites that 
activate channel are indicated with a plus. The cytosolic Ca2+ inhibitory site is marked with a minus. Reproduced 
with the permission from: Qin J, Valle G, Nani A, Nori A, Rizzi N, Priori SG, et al. Luminal Ca2+ regulation of 
single cardiac ryanodine receptors: insights provided by calsequestrin and its mutants. J Gen Physiol. 
2008;131(4):325-34. Epub 2008/03/19. 
 
The two forms of calsequestrin, cardiac and skeletal are both located in the ER and in the 
lumen of the sarcoplasmic reticulum (SR) however, the two isoforms polymerize in different 
compartments of the ER. Cardiac calsequestrin is found in the most proximal ER exits sites 
whereas the skeletal calsequestrin is on the opposite side, concentrating on the distal part of 
the ER (29). Recent reports show the presence of CASQ1 protein in thyroid tissues (30). It is 
conceivable to think that this research may open the way to challenging questions about the 
role(s) of calsequestrin in calcium homeostasis and its interactions with other intracellular 
proteins in the thyroid tissues of patients suffering from thyroid diseases  
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The genetic factor in TED     
It was reported by Porter et al (14) that CASQ1 gene was expressed in the extraocular muscle 
4.7 times more than in other skeletal muscle while others (7) showed that CASQ2 was 
expressed 2.7 times more. Our team was the first to show the presence of CASQ protein in 
the thyroid tissue. Recently, a comprehensive detailed molecular study of TED using micro 
array technology showed that 295 genes were differentially expressed in thyroid tissues from 
patients with Graves’ hyperthyroidism with and without ophthalmopathy. Of these, the 
cardiac calsequestrin gene (CASQ2) was the most highly expressed gene in GO (2.2-fold 
increase, p < 0.05) (7).  
These and other recent studies confirm the potential importance of the CASQ protein in the 
pathogenesis of TED. A critical role for CASQ2 in maintaining cardiac muscle function has 
been confirmed by the recently identified missense mutation, producing a single amino acid 
substitution (D307H), in a family suffering from an autosomal recessive catecholamine-
induced polymorphic ventricular tachycardia (31). These emerging reports raise the 
possibility that skeletal CASQ1 polymorphisms may be associated with skeletal muscle 
myopathies.  
 
The complexity of GO indicates that GO is a genetically heterogeneous disorder with 
different genes, gene-gene, and gene-environmental factor interactions causing the same 
phenotype (22, 32-35). Although a large number of association studies with candidate genes 
in GO have been published, the results are so far inconclusive. It should be noted that the vast 
majority of studies are underpowered and the GO groups poorly characterized (reviewed in 
(36, 37)).  
In this study , initially,  8 pathogenic SNPs identified in a cohort of 86 patients and the normal 
control by High through put IPLEX technology using MassARRAY System through single 
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base primer extension to identify the informative SNP(s). In subsequent studies, when the 
number of patients in the cohort increased to 440, 4 of these 8 identified pathogenic SNPs 
were present in all the patients and showed to be informative. Therefore, it was considered to 
carry out a case control association study investigating these 4 SNPs in CASQ1 gene in 
patients with various manifestations of TED.   
CASQ antibodies have shown to have good specificity as markers for early eye muscle 
inflammation process in patients with GO (38). The eye muscle antibodies such as CASQ1 
and COL XIII antibodies are also present in those cases where disease symptoms and/or TSH-
r antibodies are absent.  
 
Recent studies investigating the genetics behind calsequestrin demonstrated that CASQ1 gene 
has been involved also in heat strokes and hyperthermia in mice (25, 39) due to its knockout 
from their genotype. Similarly, a critical role of CASQ2 protein exacerbates cardiac muscle 
functions through a missense mutation in a family with associated autosomal recessive 
catecholamine-Induced polymorphic ventricular tachycardia (31).  
It remains to determine whether the identified polymorphisms may play significant role(s) in 
the pathogenesis of TED.  
 
Polymorphisms in casq1 gene 
Polymorphisms in calcium binding protein CASQ1 have been mainly associated with type 2 
diabetes in many studies (9). In silico studies of CASQ1 gene (see the methods chapter for 
detail) showed the presence of 33 out of 122 reported polymorphisms to be conserved. These 
33 SNPs were studied by IPLEX MASS-ARRAY technologies. Four polymorphisms showed 
to be informative and significant. They are as follow:    
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rs74123279 SNP found in the promoter area of CASQ1 gene might play a modulatory role in 
transcription of CASQ1 gene. In fact its change from G to A causes a loss of transcription 
factors such as CTCF (40) and BORIS (41) gene family transcriptional regulators with 11 
highly conserved zinc finger domains (unpublished work).  
rs3838216 SNP in Intron 1 has been evolutionary conserved and recent preliminary studies 
show an association to thyroid disorders (Graves’ ophthalmopathy) (42).  
rs74123289 SNP located in Exon 11 3’UTR shows a change from C to T. Such alteration 
indicated that this region may be a control region for the translational activity of CASQ1 gene 
through a binding site for MicroRNA (mir-224) (unpublished work). MicroRNAs are small 
molecules of RNA that are not codified, usually of a length between 20-22 nucleotides. These 
molecules are part of a net of regulatory genes and have various functions, among which, the 
most known is the post-translational regulation (inhibiting the messenger RNAs).   
rs17368853 SNP in Intron 9 is located in a highly evolutionary conserved region containing a 
transposon element. Preliminary studies conducted on this SNP have indicated that the region 
of the intron 9 may be deleted or absent in CASQ1 gene of patients suffering from severe 
ophthalmopathy (unpublished work and  http://ecrbrowser.dcode.org/).  
  rheMac2 ATTTTGTTCTCAGCTACATTCCTAACACCTAGCACTCATTGTTGAATGAGTACCTGAAAG 
          |||||||||||||||||||||| ||||||||||||||  |||||||||||||  ||||||| 
     hg19 ATTTTGTTCTCAGCTACATTCCCAACACCTAGCACTCGCTGTTGAATGAGTAACTGAAAG 
          160169193           160169213           160169233            
 
          138821300           138821320           138821340            
  rheMac2 AACAAAGAGAAACGTGAGACGCATTGGCACTTACCAGGTATACTTGCCTTATTTCAGAAA 
          |||||||||||||||||||  ||||||||||||||||||||||||||||||||| ||||| 
     hg19 AACAAAGAGAAACGTGAGAAACATTGGCACTTACCAGGTATACTTGCCTTATTTTAGAAA 
          160169253           160169273           160169293            
 
          138821360           138821380           138821400            
  rheMac2 TGTAAGATCGGAGGGCCAGAGAGAAGTGACTTGACCTTGAACACAAGGATCTGATCCAGG 
          ||||||||| |||||||||||||||||||||||||||||||||||||||||||||||||| 
     hg19 TGTAAGATCTGAGGGCCAGAGAGAAGTGACTTGACCTTGAACACAAGGATCTGATCCAGG 
          160169313           160169333           160169353            
 
          138821420           138821440           138821460            
  rheMac2 ATCAGAGCAGGGTTTCCTATCTAGTTTTCCTTAGAAAAGAGGGGCCAGTATGCCTGGCTG 
          |||||| |||||||||||||| ||||||||| |||||||||||||||||   ||  |||| 
     hg19 ATCAGAACAGGGTTTCCTATCCAGTTTTCCTCAGAAAAGAGGGGCCAGTGCACCCAGCTG 
          160169373           160169393           160169413            
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The two sequences aligned above belong to the human (hg19) and the rhesus macaque 
(rheMac2) CASQ1 protein. This particular region in green, flanked by the intronic regions in 
dark pink, of the CASQ1 gene could be a transposon site. Transposons are notorious elements 
of the genome that have the ability to move from a gene to another. This process, in which 
they are involved, is known as “transposition” and require the presence of recombination’s 
sites on the DNA, located both on the transposon and on the target chromosome. These 
elements, flanked with particular sequences of insertions, may have been removed, or located 
elsewhere, in patients with severe ophthalmopathy not allowing those individuals to express 
calsequestrin-1 in a correct way or sufficient quantity. 
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Chapter II: Methodology 
- SNPs study - 
 
Introduction 
           The complex modulation of the human genome is subject to many kinds of alterations, 
along with insertions, deletions, repetitions and, of course, polymorphisms. Single nucleotide 
polymorphisms in calsequestrin gene are potential genetic modifiers.  
Previous studies, targeting casq1 gene polymorphisms, have suggested an association 
between calsequestrin-1 protein and type 2 diabetes (8, 9). In other studies, the upregulation 
of the cardiac calsequestrin gene has been reported in patients with Graves’ ophthalmopathy 
(7), supporting its role as trigger for these pathology. Furthermore, examples of specific and 
sensitive affinity between antibodies targeting CASQ1 protein and ophthalmopathy have 
suggested being an alternative to TSH-r as future screening marker (13). 
The identification of 4 informative SNPs in calsequestrin-1 gene has given strength to the 
hypothesis that sees calsequestrin-1 to have a genetic role in this particular disease context. 
 
Previous studies from our laboratory 
Microarray results from previous studies carried by our research group identified 295 genes 
that were differently expressed in patients with and without ophthalmopathy. Specifically, it 
showed that the CASQ1 and CASQ2 genes were upregulated in thyroid tissue in patients with 
Graves’ disease after thyroidectomy. The cardiac calsequestrin gene was found to be 
upregulated in patients with Graves’ disease and TAO. The skeletal calsequestrin gene was 
upregulated as well, but not significantly. These findings have raised the question of whether 
the binding of the antibodies occurs on the shared epitopes. The latter hypothesis was lately 
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disproved by the same research group (43) through the measurement of antibodies against 
CASQ1 and CASQ2 using enzyme-linked immunosorbent assay (ELISA) from patients with 
and without ophthalmopathy. Following studies then narrowed to CASQ1 because of the over 
expression in the extraocular muscle (EOM), 4.7 times more than in the jaw muscle, whereas 
cardiac calsequestrin was only 2.7 times more in EOM  (14)  
fetal 
brain 
whole 
brain 
temporal 
lobe 
parietal 
lobe 
occipital 
lobe 
prefronta
l cortex 
cingulate 
cortex 
cerebellu
m 
cerebellar 
peduncle amygdala 
hypothal
amus thalamus 
subthala
mic 
nucleus 
caudate 
nucleus 
globus 
pallidus 
olfactory 
bulb 
pons medulla oblongata 
spinal 
cord 
ciliary 
ganglion 
trigemina
l ganglia 
superior 
cervical 
ganglion 
dorsal 
root 
ganglia 
thymus 
tonsil lymph node 
bone 
marrow 
BM-
CD71+ 
early 
erythroid 
BM-
CD33+ 
myeloid 
BM-
CD105+ 
endotheli
al 
BM-
CD34+ 
whole 
blood 
PB-
BDCA4+ 
dendrite 
PB-
CD14+ 
monocyte 
PB-
CD56+ 
NKCells  
PB-CD4+ 
Tcells 
PB-CD8+ 
Tcells 
PB-
CD19+ 
Bcells 
leukemia 
lymphocy
te 
721 B 
lymphobl
ast 
lymphom
a Burkitt 
leukemia 
promyelo
cytic 
lymphoma 
Burkit... 
leukemia 
chroni... 
colorectal 
adenoma Appendix skin Adipocyte 
fetal 
thyroid thyroid 
pituitary 
gland 
adrenal 
gland 
adrenal 
cortex Prostate 
salivary 
gland Pancreas 
pancreati
c islets 
atriovent
ricula... heart 
cardiac 
myocytes 
skeletal 
muscle Tongue 
smooth 
muscle uterus 
uterus 
corpus trachea 
bronchial 
epitheliu
m 
fetal lung lung Kidney fetal liver liver 
placenta testis 
testis 
Leydig 
cell 
testis 
germ cell 
testis 
interstitia
l cell 
testis 
seminifer
ous 
ovary 
 
 
Figure 8.  Organs distribution of CASQ1 proteins; deep red colour indicates high levels of  expression of 
protein.  Skeletal muscles have high levels of CASQ1 protein, other tissues such as tongue, thyroid, Heart and 
uterus corpus have relatively high concentration of CASQ1 protein (source: www.ecrbrowser.dcode.org).  
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Present studies, results and findings  
Analysis through ECR browser (http://ecrbrowser.dcode.org/) aligned CASQ1 gene of several 
species (Fig. 9), such as lampreys, fugu, xenopus, dog, marsupial, mouse, and rhesus monkey 
with the human sequence. The result of this analysis showed the conserved elements between 
the different genomes. The yellow regions are untranslated 5’UTR where the gene promoter is 
located and 3’UTR where the stop signal is located. Blue sections are exons, of which 
CASQ1 gene has 11; dark pink regions between the exons are introns. CASQ1 has 10 introns, 
within its intronic regions there are highly conserved intergenic subregions, indicated by the 
green colour, these are transposons and repetitive elements.  
 
 
 
Figure 9. Whole genome alignment of different species showing, in green, highly conserved regions of 
calsequestrin-1 gene, the baseline represents the human genomic sequence. Yellow regions are untranslated 
5’UTR (left side of the figure) where the gene promoter is located and 3’UTR (right side of the figure) where the 
stop signal is located. Blue blocks are exons, and CASQ1 gene has 11, whereas the dark pink regions are introns. 
CASQ1 has 10 introns, within these regions there are highly conserved intragenic regions indicated by the colour 
green. These green coloured regions are transposons and repetitive elements. Abbreviations on the figure are the 
followings: galGal3 (chicken), fr2 (fugu), xenTro2 (xenopus), momDom4 (opossum), canFam2 (dog), mm9 
(mouse), rheMac2 (rhesus macaque) 
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The comparison of the 11 Kb human genomic region on chromosome 1, including non-coding 
parts of the gene and the ~5 kb downstream and ~5 kb upstream intergenic regions, with the 
corresponding mouse sequence, resulted in the identification of 27 conserved DNA sequences 
that met the criteria of at least 100 bases in length and at least 70% identity. The intragenic 
regions of the gene contain 13 conserved non-coding sequences, mostly with 90% identity or 
more. Further 8 sequences are located downstream and other 6 upstream of CASQ1 gene. 
The whole calsequestrin-1 sequence was then processed using ECR browser to extrapolate the 
list of the SNPs for the designing of the primers that would cover the entire gene. The 
conserved regions showed 122 polymorphisms in CASQ1 gene, 33 of which were highly 
conserved and 22 were in the human sequence (Fig. 10).  
 
Figure 10.  CASQ1 gene sense strand, or + strand, indicated by the arrow to the right. The arrows at the bottom 
of the figure indicate the 22 conserved SNPs in human calsequestrin-1 gene.   
 
 
Genomic DNA purification from white blood cells 
Genomic DNA was isolated from patients’ blood with thyroid disease (Graves). Promega 
genomic DNA purification kit was used for this purpose. The blood samples were sorted in 
4x300 µl clean, DNase, RNase, pyrogen free 1.5 ml tubes, 900 µl of cell lysis solution have 
been added to each tube and inverted 5-6 times. Incubated at RT for 10 min the tubes have 
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been inverted 2-3 times to lyse the remaining red blood cells and then centrifuged at 18000g 
for 1 min for each 300 µl sample. The supernatant from the blood was aspirated and 300 µl of 
nuclei lysis solution were added to the pellet to completely lyse the white blood cells and then 
incubated for 1 hour at 37°C. RNase solution, 1.5 µl in volume, was added to each tube and 
gently mixed by inverting them before incubation at 37°C for 15 minutes. After 100 µl of 
protein precipitation solution was added to the tubes they were vortexed for a few seconds 
and then centrifuged again at 18000g per 10 min at RT. The supernatant was then transferred 
to a new, clean set of 1.5 ml tubes containing 300 µl of isopropanol and then gently mixed 
until a white thread of DNA became visible. Centrifuged at 18000g for 5 min at RT the 
samples’ supernatant was then gently decanted and a 100 µl volume of 70% ethanol (stored at 
-20°C) was added and gently washed by several rotations. A further centrifugation at 18000g 
for 5 min was completed and the ethanol aspirated, letting the solution to air-dry for 10-15 
min. DNA rehydrating solution, 100 µl per tube, was added before incubating the tubes at 
65°C for 1 hour and then stored at 2-8°C until it was used. To measure the purity of the DNA 
extracted each tube has been measured with the spectrophotometer at length between 260 and 
280 nm. The DNA samples isolated and stored in 4 different tubes each have been added 
together and diluted 1:10 into a 0.5ml tube. The concentration of the DNA was then 
normalised to 50 µg/ml of DNA. 
 
Primers 
The next step in the research was to design primers that would cover the entire gene. 
Invitrogen customer primer design tool was used to select the correct forward and reverse 
primers that would respect the following criteria: 
• Melting temperature of the primers; 
• % of GC, between 50 and 60%;  
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• Avoiding terminations in T or A, because of the possible dimerization with other primers 
that would cause the PCR product to be an underestimation of the results.  
Once the 15 forward and reverse primers (Table 2) arrived they were reconstituted using TE 
(10mM Tris-HCl, pH 8.0, 1mM EDTA) added at proper volume according to the 
manufacturer’s instructions. The reconstituted primers were then stored at -20°C until use. 
Promoter rs7412379 forward AGC CCC AGC TTC ATT TAC CT 
Promoter rs77412379 reverse CCC ACC TGG TCC TGT CTA AA 
5UTR Exon 1 rs74123280 forward ATT CCT CCA CCT GAC CCT TT 
5UTR Exon 1 rs74123280 reverse CCC CAT CCT GTC TGT AGC AC 
Exon 1 rs35923530 forward GCT AGG GAC ACC CAA GTC AG 
Exon 1 rs35923530 reverse CTC ACC TCC AGG ATC AGC TC 
Exon 3 rs3747623 forward GAT TAT CAA ACG GGC TGT GG 
Exon 3 rs3747623 reverse CCA GGG GAG TCC TTA CAT CA 
Exon 4 rs34415466 forward CAC ACA CCC ACA CAC TGT CA 
Exon 4 rs34415466 reverse GTG AGA TGG GGA TCC AGA GA 
Intron 1 rs3838216 forward TAT GGT TGC AGG AGG TGT CA 
Intron 1 rs3838216 reverse AGG GGT GCA CAA AAT GAG AG 
Intron 3 rs67278792 forward CTA CCA ACC CCA ACC TGA CA 
Intron 3 rs67278792 reverse CAT GTG GTG TGT GTG TGC AT 
Intron 4 rs2275703 forward TCT CTG GAT CCC CAT CTC AC 
Intron 4 rs2275703 reverse GTC AGT CTC TGG GGA AAC CA 
Intron 5 rs3818952 forward CAA CCC CAG GCA AGT TAA GA 
Intron 5 rs3818952 reverse CCA TGA AGG CCT CGT AGA AA 
Intron 6 rs2275704 forward ACC TTC GTG GAG GAG CAC AG 
Intron 6 rs2275704 reverse CAC TGG TGC CCA AAG TGT ATT 
Intron 9 rs12132035 forward GGC CTT GGA CTG TGA CAT CT 
Intron 9 rs12132035 reverse TGT GCC TCA CAA CAT TGG TT 
Intron 10 rs12133035 forward TGG TCC CAT ACT GGG AGA AG 
Intron 10 rs12133035 reverse GAA TTT GAA CTG GGC CCT GA 
Exon 11 rs13375800 forward ACC AGG CCA GCT CTC TCT TA 
Exon 11 rs13375800 reverse GCC AAG GAC AGG ACA GTC AG 
Exon 11 rs74123288 forward CCC ACT GGT CTT TTC ATG CT 
Exon 11 rs74123288 reverse GAG AGC TGG CCT GGT GTC TA 
Exon 11 rs74123289 forward ATA TGC TGG GTG CTG AGA CA 
Exon 11 rs74123289 reverse TGC ATA GAT GGA GGG AAC AG 
 
Table 2. List of CASQ1 primers (forward and reverse) designed to cover the whole CASQ1 gene and ordered 
through Invitrogen. 
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Polymerase Chain Reaction (PCR) 
Use of PCR technique was involved to provide evidence on the correct amplification of the 
gene. The first PCR screening was carried on 21 samples only and the patients’ amplifications 
(Fig. 13) frequently lack of the gene region amplified by the 11th primer (Fig. 14a-14b), the 
region amplified by the 11th primer covered intron 9 region of the gene, previously mentioned 
to be site where one of the SNPs of our interest is located (rs17368853).  
ctgctatcttaaggtggggccttggactgtgacatcttcttagtgagggc  
tttgtttcagaggtcccatccccacctcctagctggggggccctgggagg Intron 9  
gtatgcgtgttgcatgcttaagggcactgttggcatggagggcatcctga G- T 
gcaaggggaaacaggacggacatcacacacattcccagagcagaggctgg rs12132035 
atgggtagctcaggtgctagggctgactcctaaagaaaaccaatgttgtg 
aggcacaatagtcctgcacatgggtatacacactcaatcatagaatcata 
gcacagagattccctgtttcaggagatgattttgttctcagctacattcc 
caacacctagcactcgctgttgaatgagtaactgaaagaacaaagagaaa rs17368853 
 
cgtgagaaacattggcacttaccaggtatacttgccttattttagaaatg G -> A 
taagatctgagggccagagagaagtgacttgaccttgaacacaaggatct 
gatccaggatcagaacagggtttcctatccagttttcctcagaaaagagg 
ggccagtgcacccagctgaccctcccgattctctccctttaggatttctc 
ctcttttgttgtttagttctacccttgccttgatgccctcacaggtggac 
ctgtccccatccactgccagttcgcactgtcccctctccatccctgggct 
gaccctcacactcatcctcctggattcatgtgctccctagtatctattaa 
gttgctgtattttgatctctctacagCTGGTCCCATACTGGGAGAAG 
 
The sequence above belongs to the human CASQ1 protein, in particular the region where 
intron 9 sits. The sequences highlighted in dark red are the primers designed to replicate the 
region in between. The section highlighted in pale blue is the one that contains the 
polymorphism. It might be that in patients the transposon region, normally inactive and non-
movable, becomes active and in the moving it brings with it flanking regions causing the non-
amplification of the region. 
The amplification of each patient’s CASQ1 gene was done using a polymerase chain reaction 
(PCR) technique. The PCR master mix (MM) included the following buffer: 166 mM 
(NH4)2SO4, 670 mM Tris-HCl, 37 mM MgCl2 working into a pH range between 8.0 and 8.3. 
The reagents added to the MM were the following: 14.2 µl dH2O, 3 µl 10x buffer, 4.5 µl 
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dNTP (5 mM), 1.5 µl DMSO (1 M), 3 µl Betaine (5 M), 0.3 µl Life Technologies Platinum 
Taq DNA Polymerase, 1 µl primers (5 picmol/µl), 2.5 µl DNA (20 ng/µl). The reactions were 
performed using an MJ Research PTC-200 Peltier Thermal Cycler machine sat on the 
following protocol:  
- Denaturation 95°C for 7 min 
- Amplification’s cycles: 
- 72°C for 5 min (stored at 4°C O/N) 
The amplified samples were ran on the gel prepared on the day with 3g of agarose type I in 
100 ml stained TEA 1x (SYBR Save DNA gel stain 10,000x concentrate in DMSO, 40 µl per 
1L of TEA 1x) and microwaved until boiling before the DNA was added to the wells, then 
poured into the assembled chamber with an 18 well comb. The chamber was filled with TEA 
1x and 10 µl of each sample was mixed with 1 µl of Bio-Rad Nucleic Acid Sample Loading 
Buffer 5x. The marker used was: of Bio-Rad EZ Load 100bp Molecular Ruler and 5 µl were 
added as reference to our PCR products. The gels were ran at 100 V per ~1 hour for a good 
bands’ separation. Sequence of Primers and the regions for amplification)  
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- Western Blot study - 
 
Introduction 
Early results from our laboratory showed that the calsequestrin-2 gene was up-
regulated in thyroid tissue from patients with Graves’ ophthalmopathy (GO) compared to 
those with no eye signs.  
The aim of this study was to measure the CASQ1 protein levels in thyroid tissue extracts from 
patients with Graves’ disease with and without ophthalmopathy and control subjects, which 
were patients with thyroid carcinoma, by quantitative Western blotting. 
We hypothesize that CASQ1 concentration in thyroid tissue from patients with Graves’ 
hyperthyroidism (GH) or GO are different compared to the ones found in normal thyroid 
tissue and that these differences may reflect either autoimmune reaction or hyperthyroidism. 
 
Samples size and subjects’ clinical description  
Thyroid tissue was obtained fresh at thyroidectomy from 28 patients with Graves’ disease, 6 
males and 22 females aged 11 to 75 (mean age 36.29 yr) of whom, 2 males and 5 females 
aged 17 to 75 (mean age 43.71 yr) had obvious ophthalmopathy, 22 patients, as control 
thyroid with multi-nodular goitre, thyroid cancer or toxic nodular goitre, 4 males and 19 
females aged 35 to 82 (mean age 43.92 yr) (Table 3). The diagnoses of the various disorders 
were based on standard clinical criteria and confirmed by thyroid function testing, thyroid 
ultrasonography and immunological tests.  The grade, severity and activity of any associated 
ophthalmopathy were classified as: I) Nunery types 1 (without restrictive myopathy) or 2 
(with restrictive myopathy) (3) II) the clinical activity score (CAS) (0-10) of Mourits et al. 
(19) which is a measure of disease activity and III) Werner’s NOSPECS class (44). For the 
purposes of the present study “obvious” ophthalmopathy was defined as a CAS of 3 or more 
plus a NOSPECS class 2 or more. Isolated upper eyelid retraction and/or lag were not taken 
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as “ophthalmopathy”. All patients, GH and GO, are treated with anti-thyroid drugs before 
surgery and a total thyroidectomy was performed as an alternative to radio iodine therapy, the 
effect of these drugs on calsequestrin-1 protein expression is unknown.  
Local Ethical Committee approval was received for the study and informed consent of 
participating subjects was obtained. 
Group Number Mean age (years) 
GRAVES’ DISEASE 28 36.29 
Males 6  
Females 22  
GRAVES’ 
OPHTHALMOPATHY 
7 43.71 
Males 2  
Females 5  
CONTROL 22 43.92 
Males 4  
Females 18  
Table 3. Demographies and clinical details in population of patients with thyroid autoimmunity and control 
subject without autoimmune disease. 
 
Quantitative Western Blotting methodology 
A quantitative western blot method was used to measure concentrations of the CASQ1 protein 
in cellular extracts of thyroid tissue. Test and control (normal) thyroid tissue specimens were 
collected at thyroidectomy and stored at -70°C until used. Frozen tissues were thawed on ice, 
minced to small pieces in homogenisation buffer. 
Every tissue sample was left in 1 ml Whole Cell Extract Lysis Buffer for the whole process of 
protein extraction. This buffer was made of:  
• 400 µl of 400mM KCl;  
• 50 µl of 50 mM Hepes pH 7.4;  
• 3 µl of 1.5 mM EDTA ph 8.0;  
• 1 µl 1 mM DTT; 
• 200 µl 100% Glycerol; 
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• 100 µl of 10 mM Na2MoO4 (Sodium Molybdate); 
• 100 µl of 20 mM NaF (Sodium Fluoride); 
• 10 µl of 100 µM Na3VOH (Sodium Orthovanadate); 
• 5 µl of 0.5% Tergitol-type NP-40 (IPGEL); 
• 100 µl of β-glycerol P 20 mM; 
• 10 µl of Proteases inhibitors (100 x 1ml); 
• 2.3 µl of PMSF (added at the end because of its high sensibility); 
• 18.7 µl of dH2O to adjust the total volume of the solution; 
 
The whole process of lysis of the tissue cells had been done on ice to preserve the stability of 
the proteins within the tissue and to avoid the proteases to start degrading the rest of the cells. 
After being homogenized the samples have been centrifuged for ~1 hour at 18,000 g in the 
cold room and the supernatant collected. Total protein concentrations from each patient were 
measured by performing an ELISA test, BCA Protein Assay Kit from Thermo Scientific 
according to manufacturer’s instructions. 
Equal amounts of patients’ thyroid tissue extracts, 50 µg/ml, were loaded onto NuPAGE® 
Novex 4-12% Tris-Bis gels. Following electrophoresis, samples were transblotted to PVDF 
membranes, incubated with a 1:1000 dilution of calsequestrin 1 antibody (Santa Cruz Biotech 
c#:H-60), a rabbit polyclonal IgG (Santa Cruz Biotech c#:sc-28274). The secondary antibody 
was diluted 1:10,000 and it was an HRP-conjugated goat anti-rabbit antibody (Santa Cruz 
Biotech c#:sc-2004), or anti-mouse antibody for GAPDH (Millipore c#:MAB374). Membrane 
proteins were identified by chemiluminescence using SuperSignal Western Blot Kit and 
scanned in a Universal gel documentation Hood using Quantity One 4.4.0 ChemiDoc 
software which enumerates the pixels in matching CASQ1 and GAPDH bands (Fig. 11) from 
which the CASQ1 protein concentration can be determined as a CASQ1:GAPDH ratio.  
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Figure 11. Illustration of bracket quantitation used by the software to determine the density of the band and from 
there calculating the concentration of protein with extreme precision (45). 
 
Using CASQ1 protein standards (Fig. 12), the protein levels are determined as pmol 
CASQ1/mg total thyroid proteins in the extracts, for both the 50 kDa and 60 kDa forms of the 
protein. 
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Figure 12. Calsequestrin-1 standards read with Quantity One 4.4.0 ChemiDoc software and plotted to generate 
the equation then used to calculate the amount of CASQ1 protein per patients. 
 
Quantity One 4.4.0 ChemiDoc identifies the bands by quantitating the average intensity of the 
bands scanned and selected by the user. The intensity profile of each band is then processed to 
have a result in INTENSITY x mm, expressed in Table 4. 
__________________________________________________________________________________ 
Gel name : GEL 1 56-62 9-5-2012 2 (Raw 1-D Image) 
Index Name Volume   Concentration Area   Density 
  INT*mm2    mm2   INT/mm2 
1 U1 27273.7640612447 N/A              129.8014372432 3098.3324109616 
2 U2 15953.9801007835 N/A    80.5664093234 2919.9638158850 
3 U3 14868.5715307326 N/A                89.8573167958 2439.9348636031 
 
Table 4. Program output of three selected bands from a scanned gel. Volume and Density values of each band 
are then used to calculate the ‘weight matrix’, which represents the ‘y’ in the linear equation extrapolated from 
the CASQ1 plotted standards. 
 
Once we have the values in nanograms of CASQ1 protein we can determine its ‘weight 
matrix’ (Table 5) we then determine the weight matrix for GAPDH (Table 6), relative to the 
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same subjects. The ratio of the two matrixes is used to correct the nanograms values for 
CASQ1 protein. The protein concentrations, nanomoles of CASQ1 over milligrams of extract 
(Table 7), is then obtained. 
 
Subject 
# 
Gel 1 Upper 
band  
Volume 
Gel 1 Upper 
band  
Density 
Gel 1 Upper band 
(weight matrix) 
(Vol * Density) 
The ‘y’ in the CASQ1 standards’ 
equation  
ng of CASQ1 protein 
 
The value of ‘x’in the 
equation  
56 27274 3098 84494852 216 
57 15954 2919 46569726 110.292 
58 14868 2439 36263052 81.5645 
 
Table 5. Weight Matrix for CASQ1 bands and ng of protein on each band on the gel. 
 
Volume of 
GAPDH 
Density of 
GAPDH 
Weigh matrix 
for 
GAPDH 
Weight Matrix of CASQ1/ Weight matrix of GAPDH 
(ratio of changes for loading to gel) 
9091 1797 16336527 5.172142892 
6188 1649 10204012 4.563864292 
5062 1541 7800542 4.6487862 
 
Table 6. Weight Matrix for GAPDH, ratios of the weight matrixes used to adjust CASQ1 protein ng values. 
 
 
 
 
 
46 
 
Corrected ng of 
CASQ1 
(ratio * nanograms) 
nmol of CASQ1 = 
ng/60000 dalton 
(weight of the upper 
band) 
pmol  of CASQ1 
= nmol*1000 
pmol CASQ1/mg total protein 
extract = (pmol*1000 /0.05 mg 
protein loaded on the gel) 
1117.184306 0.018619738 18.61973844 372.4 
503.3582875 0.008389305 8.389304792 167.8 
379.175834 0.006319597 6.319597233 126.4 
 
Table 7. Corrections according to the weight of the band (50kDa or 60kDa, respectively, lower and upper band). 
Final values for CASQ1 protein expressed as picomoles over milligrams of total protein from each extract. 
 
This method of obtaining CASQ1 protein levels can be achieved thanks to the great precision 
of the software used. The reason for these calculations is that having a concentration, instead 
of a ratio of CASQ1 and GAPDH, allows our results to be compared to others with a great 
level of precision.  
 
 
 
 
 
 
 
47 
 
Chapter III: Results and discussion from 
SNPs study 
Introduction 
The results from this first part of the study might change a little, maybe expand, the 
way casq1 gene roles are seen within the Graves’ disease context. This study identifies 4 
informative SNPs in calsequestrin-1 gene, each of them with their entourage of speculations 
over the effect and function implicated in different aspects of the protein’s roles. 
  
Materials and methods 
Use of bioinformatics tools, such as http://ecrbrowser.dcode.org/, has been extensively 
employed to circle the ‘critical’ SNPs in casq1. Subsequently a set of primers have been 
designed to specifically cover the entire length of the gene. Ultimately, PCR technique was 
involved to amplify the entire casq1 gene. 
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Results from SNPs study 
 
                   
 
Figure 13. Typical gel image of PCR product lacking the amplification of the gene covered by the 11th primer. 
The latter primer covers the region of the calsequestrin-1 gene where Intron 9 is present, spot of a highly 
conserved polymorphism. Lines 1, 2 and 3 ran the primers that covered the first part (promoter area) of CASQ1 
gene, the not amplification of these regions is maybe due to the fact that the promoter region was rich in GC 
content and the polymerase enzyme couldn’t continue the transcription. These regions of the gene also included 
SNPs. 
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            a)                      b) 
 
 
Figure 14a. Gel amplifications of a control patient 14b. On the gel, circled, absence of amplification of section 
11 that covers intron 9 region on CASQ1 gene. This part of the gene also contains transposons that are normally 
inactive and not moveable.  
 
Subsequently, CASQ1 polymorphisms were genotyped from a bigger cohort of 183 subjects 
(Table 9) that included patients with Graves’ disease or Hashimoto’s thyroiditis and normal 
subjects used as controls. DNA samples were extracted from patients and controls white 
blood cells and purity of the DNA was assessed. The samples were then normalized to 400 ng 
of DNA in a 96-well plate template as requested by AGRF (Australian Genome Research 
Facility) and sent for sequencing using MassARRAY  SNP analysis (a technology used for 
SNP genotyping, methylation detection and quantitative gene expression analysis) using 
iPLEX technology of SEQUENOM. iPLEX is another type of technology developed by 
SEQUENOM, it allows to genotype polymorphisms in genes associated with drug absorption, 
distribution, metabolism, and excretion. 
        Control                                               Patient 
 
          1--2--3-4--5--6--7-8-9-10-11-12-13-14-15-16  
        1   2  3  4   5  6  7  8   9 10 11-12-13-14-15 16  
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The study identified the presence or absence of the 22 SNPs and the data generated narrowed 
down the initial selection from 22 to only 8 SNPs (Table 8) through selection criteria such as 
Chi-square and p-value (Table 10). Although at the beginning of the study the cohort wasn’t 
big enough it showed a tendency to the significance of some of the SNPs. During the analysis 
the equilibrium of the alleles’ frequencies was respected (Hardy-Weinberg equilibrium). 
Other statistical analysis like “Linkage disequilibrium” would have been a useful tool to 
identify small chromosomal regions such as the one discussed in this thesis, but at that stage 
the sample size wasn’t big enough. 
 
SNP position, name and 
modification 
SNP sequence 
Promoter   rs74123279     
G  A 
Gagggaaggagcccctgggagcctg 
gggtagaagtgtaggaggtgggaggat  
Exon 1 UTR before ATG start, 
rs74123280   
A  G 
Ccctt 
GGCTCTGTCGGCAGTTTCTCCAGGACCCAGCAGTGCC
CTCTGTCCAC 
Intron 1  rs3838216                       
[-/ggcattcagataggcct] Insertion  
agctcct
gtggccccttctctggcct cagcttgtccagagcttggagcatt 
Intron 2   rs3747623  
C  T 
 gaagcctgggatcatggctcactaccccaccc  
ctgcgcccggctcactccct 
Intron 4   rs2275703    
A  C  
tgtactctgggggttcccagacaagcacctccagtattccaccttc  
Ccctca 
Intron 9   rs17368853    
G  A 
agctacattcc  
caacacctagcactcgctgttgaatgagtaactgaaagaac 
Intron 10   rs55887151                  
A  G 
Ggaagttcagtgtggcaagagcacgggagacagattgaaggg 
agaaggtcta 
Exon 11   rs74123289    
C  T 
TTTTCCCTAGACACCAGGCC 
AGCTCTCTCTTATCTGACTTCTGTTTCTTATC 
 
Table 8. Sequence of the 8 highly informative SNPs identified in CASQ1 human gene, in red the promoter, dark 
yellow for the exons and turquoise for the intronic sequences. 
 
51 
 
  
Table 9. Genetic parameters used to identify informative SNPs in the cohort of 183 DNA samples from patients 
with thyroid autoimmune disease and normal controls. Chi Square and P values tests were performed to confer 
statistical relevance to the observations. Hardy-Weinberg equilibrium respected (major allele + minor allele = 
frequency of 1). 
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Table 10. Statistical selection criteria used to determine which SNPs to choose. P-values indicated in the 
“Significance” column indicate a tendency towards the significance. 
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Table 11. Genetic parameters used to identify informative SNPs in the cohort of 183 DNA samples from 
patients with thyroid autoimmune disease and normal controls. Tha table shows: the SNPs tested (Assay 
column), the position on the gene (SNP position), the alleles changes of base (Alleles), the ancestral allele 
(Ancestral Allele), the gene on which the SNPs are analysed (Gene(s)), the region those SNPs are in the CASQ1 
gene (Role), and the effect those changes in base have on “Amino acid change”, Amino acid position” and “SNP 
relative to Chromosome” (minus ‘-‘ if they don’t have an effect, plus ‘+’ if those changes have an effect). 
 
 
In summary, the 8 SNPs were associated with different degrees of the diseases (Table 12): 
a) Introns 9, 4, 2, 1, 10, exon 11 and promoter SNPs in Graves’ disease without 
ophthalmopathy  
b) Introns 4, 2, 1 and promoter SNPs in Graves’ disease with Ophthalmopathy  
c) Introns 4 and 2 SNPs in Hashimoto’s Thyroiditis  without ophthalmopathy  
d) Introns 4, 2 and 1 SNPs in Hashimoto’s Thyroiditis with ophthalmopathy  
e) Introns 4, 2 and promoter SNPs in Silent Thyroiditis  
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f) Introns 4, 2 1, exon 1 and promoter SNPs in Pregnant women with Graves’ 
hyperthyroidism  without ophthalmopathy  
 
 
 
Table 12. Classification of the disease associated with informative SNPs in the first cohort of 183 subjects. The 
total number of patients tested reaches 177 because of the ~96% success rate of the sequencing machinery 
involved. The numbers in the cells of this table represent the number of patients from the cohort that fall into the 
reported categories on the axis of the table (vertical-right and horizontal-top). 
 
Use of MassARRAY SNP analysis was involved again to sequence a bigger cohort of patients 
and controls; the increase in the cohort was used to narrow down our selection to just 4 SNPs 
on which we have concentrated our study: 
1. Promoter (rs74123279);  
2. Intron 1 (rs3838216) SNP which shows a strong association to thyroid disorders (Graves’ 
ophthalmopathy) (42);   
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3. Exon 11 (rs74123289) SNP:  
                                
ATATGCTGGGTGCTGAGACACTGA  rs74123288 
TCCCCCTCATTTGATGAGCAAATGAGCTACTTTTCCCTAGACACCAGGCC 
AGCTCTCTCTTATCTGACTTCTGTTTCTTATCCCATAACTTACTTGTATC    C-T 
TATTATGTGTCTCTTCCATCACTCTCCATACTCTTTCTTGTGATTCTCCT      Exon11 
CTAGCCATATATATGGGCCCCATCTCTGTTCTGTTCCCTCCATCTATGCA  rs74123289 
 
The sequence above consists of primers (dark red sequences), transposon (green 
sequence), sequence where the SNP is located (pale blue) and exon sequence (dark pink). 
(source: www.ecrbrowser.dcode.org)  
4. Intron 9 (rs17368853) SNP in Intron 9 which has been found absent in many patients 
suffering from severe ophthalmopathy, unfortunately this type of study hasn’t been 
performed on controls (cancer  patients) because of their absence at the beginning of the 
study, but it would be a good point to expand later on when more controls will be 
collected. 
The second SNP of the list was then identified in DNA samples from 441 subjects (99 males 
and 342 females) from different groups: GO (n = 75), GH (n = 131), Hashimoto thyroiditis 
(HT) (n = 96) and control subjects (n = 108) (total of 440 due to assay failure for 1 subject) 
(Table 13).  
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Group 
 
Number (%)    Years ± SD  
Male 
 
99          (22) 41.5 ± 16.6 
Female 
 
342        (78) 49.2 ± 15.8 
Graves Ophthalmopathy (GO) 
 
75          (17) 52.4 ± 14.6 
Graves Hyperthyroidism (GH) 
 
131        (30) 48.7 ± 15.8 
Hashimoto’s (HT) 
 
96          (22) 51.8 ± 15.3 
Hashimoto’s with Ophthalmopathy 
  
4             (1) 46.5 ± 19.3 
Control 
 
108         (24) 35.7 ± 12.8 
Common Homozygote  
 
246         (56) 46.6 ± 15.8 
Heterozygote  
 
171         (39) 49.4 ± 16.8 
Rare Homozygote  
 
24           (5) 43.1 ±16.2 
Total Population Size 
 
441        (100)  
Major allele  
 
663         (75) 47.7 ± 16.2 
Minor allele  
 
219        (25) 48.6 ± 16.8 
 
Table 13. Demography, clinical details, genotypes and alleles of CASQ1 SNP rs3838216 in population of 
patients with thyroid autoimmunity and control subject without autoimmune disease. 
 
Its evolutionary preservation supports the idea that CASQ1 gene SNP rs3838216 is a genetic 
marker for ophthalmopathy in patients with GH. Potentially, after an extended study on a 
larger population with different ethnic backgrounds, rs3838216 can become a detection 
parameter for ophthalmopathy. 
The outcome of this study not only presents new ground in Graves’ disease research but also 
points to other new directions such as calsequestrin functional roles and the link to Graves’ 
disease. Such knowledge might improve screening and detection of this disease.  
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Discussion from SNPs study  
This study sat the basis for another point of view from where to look at the role of 
calsequestrin-1 in the Graves’ disease context. 
The results from this study presented a genetic perspective from where to speculate on its 2 
main findings: the 4 informative polymorphisms, regulating different features of the gene, and 
the frequent lack of the region where intron 9 stands in patients with severe TED.  
The set of 4 informative SNPs located on calsequestrin-1 gene are implicated in different 
aspects of the protein’s tasks. Functions and interactions might be affected by changes in the 
sequence of these regions. 
 
The first SNP, rs74123279, located in the promoter area, might play a reductive modulatory 
effect in the transcription of CASQ1 gene. CASQ1 protein is already present in the cell in 
very small concentrations (in the order of picomoles), a reduction in the final product could 
disrupt the cascade of fine regulation in which this protein is involved. This could be verified 
with further studies on the promoter area, designing a specific promoter with a luciferase flag 
attached to see whether there is a change in CASQ1 protein production subsequent to a 
change on concentration in thyroid hormone. 
Intron 1 contains a highly conserved SNP, rs3636216, which has shown strong association to 
Graves’ ophthalmopathy (unpublished work), later correlated to the CASQ1 protein levels in 
the second part of this study. 
Another SNP, rs74123289 located in exon 11 3’ UTR has a translational activity control role 
through the binding of a MicroRNA. The alteration of this function might alter the level of 
expression of CASQ1 protein. 
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Finally, one of the most absent region in our PCR products happened to be the one where 
SNP rs17368853 is. This polymorphism is located in intron 9 and its absence has been 
observed in many patients with severe ophthalmopathy. 
 
The last SNP of this study was observed in concomitance with the absence of amplification of 
the intron 9 region in the PCR product of the gene. This missing region is observed both in 
subjects suffering from the disease and in subjects with history of thyroid disease in their 
families.  
This region contains a highly conserved transposable element of 159 bp which is passed, or 
not passed, through the subject’s germ line to the next generation. 
Normal subjects, that don’t present any symptoms of thyroid disease, will then still have this 
missing region in the amplified calsequestrin-1 gene product through PCR. 
However, even if these normal subjects are not affected from Graves’ disease, the absence of 
this region in calsequestrin gene could affect the production of CASQ1 protein. 
The defective gene can give imperfect products and this may perhaps lead to its instability in 
patients with severe TED. 
 
With these premises is reasonable to think that CASQ1 protein product might even be 
involved in processes the protein accomplish on several levels, such as: 
• Function in terms of affinity of CASQ1 with calcium molecules; 
• Structural changes and affected capacity to store calcium; 
• Interactions with other protein partners; 
• Localisation of CASQ1 protein in sub-cellular compartmentalisation and membranes; 
• Productions of CASQ1 protein in normal levels; 
• MicroRNA levels controlling expression of CASQ1 protein; 
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Chapter IV: Results and discussion 
from Western Blot study 
Introduction 
The results from the second part of this study aimed to find a correlation between CASQ1 
protein concentration and analysed groups (Controls, GH, and GO). The underlying 
hypothesis was that the concentration of CASQ1 protein in patients affected by Graves’ 
disease, are different compared to those found in thyroids which are not engaged in 
autoimmune reactions or hyperthyroidism.  
 
Materials and methods 
This part of the study consisted in the collection of samples that respected the selected criteria 
reported in Chapter II: Methodology – Western Blot study. The latter were then subject to 
total protein extraction process, followed by protein quantification through Western Blot 
technique. The results were finally read and quantified with a Universal gel documentation 
Hood and Quantity One 4.4.0 ChemiDoc software.  
 
Results from Western Blot study 
Western blot analysis and quantitative densitometry were used to determine the concentration 
of the CASQ1 protein in extracts of thyroid tissue from patients with Graves’ disease and, as 
control, normal thyroid tissue from patients with goitre or thyroid cancer. CASQ1 protein 
concentrations on 4-12% gradient gels were determined as a CASQ1: GAPDH ratio which 
was adjusted to CASQ1 concentration namely, pmol CASQ1/mg total protein, by reference to 
a CASQ1 protein standard. Two forms of CASQ1 in the thyroid were identified, with 
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molecular weights of 50 kDa and 60 kDa respectively (Fig. 15). Quantitative assessment 
demonstrated variable levels of the CASQ1 protein in Graves’ and normal thyroid tissues 
with 17 patients showing reactivity against the 50 kDa protein and 85 patients showing 
reactivity against the 60 kDa protein. Examples of CASQ1 and GAPDH bands in 
representative patients and controls are shown in Fig. 16a-16b.  
Next, we measured CASQ1 protein concentrations in thyroid tissues from 50 patients with 
Graves’ hyperthyroidism (GH), 23 with Graves’ ophthalmopathy (GO) and in 22 control 
subjects with nodular goitre or cancer. The results are summarised in figure 17, which shows 
the mean (Control 156.71 ± 30.14; GH 41.01 ± 8.09; GO 57.08 ± 17.87 pmol/mg) 
concentrations of the CASQ1 protein in the three groups of patients. The mean concentration 
of CASQ1 was significantly reduced in patients with both GH and GO (Mann-Whitney test, p 
<0.0001, p = 0.0012 respectively) compared to the control subjects. Although mean CASQ1 
level in patients with GO was greater than that in patients with GH this difference was not 
significant (p = 0.193) (Fig. 17). Reduced thyroid CASQ1 was also correlated with the 
homozygous genotype of the rs3838216 polymorphism in the CASQ1 gene (Mann-Whitney 
test, p = 0.0223) (Fig. 18). Next we correlated serum CASQ1 antibody titres in patients with 
GH and GO (Fig. 19) with constant concentration of the CASQ1 protein in thyroid and 
thyroid gland. The aim of this experiment was to show how the immune response was related 
to the production of Abs against CASQ1 and how much CASQ1 protein was still present in 
the titres of patients with GH and GO. 
In order to determine whether the reduced CASQ1 levels in Graves’ thyroid was due to the 
autoimmune reaction or the hyperthyroidism itself, we measured the amounts of the CASQ1 
protein in toxic nodules obtained by careful sampling nodular tissues removed at 
thyroidectomy from 5 patients with toxic nodular goitre. The mean for the CASQ1 protein in 
toxic nodules was 74.5 ± 23.63 pmol/mg.  
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Figure 15. Western blotting of thyroid extracts from patients with Graves’ hyperthyroidism (lane 4), Graves’ 
ophthalmopathy (lanes 3 and 7) and (as normal thyroid) from control patients with multinodular goitre or thyroid 
cancer (lanes 2, 5 and 6), showing bands at 50 and 60 kDa. Lane 1 was an unknown thyroid patient’s sample, 
lanes 8 and 9 were, respectively, positive and negative controls. 
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a) 
 
b)
 
Figure 16a. PVDF membrane from western blotting of thyroid extract of protein from patients with Graves’ 
disease, thyroid cancer or multinodular goitre showing various CASQ1 protein concentrations 16b. PVDF 
membrane showing reactivity with GAPDH, a very abundant protein present in every cell used to normalize 
CASQ1 protein levels in thyroid extracts. Lines 1 and 2 were Controls, lines 3 to 5 and 7 were GH, line 6 was 
GO, line 8 was the standard and M as marker. 
 
63 
 
     
Figure 17. Mean (± standard error) of CASQ1 protein concentrations in thyroid tissues from patients with 
Graves’ hyperthyroidism (GH, 41.01 ± 8.09 pmol/mg), Graves’ ophthalmopathy (GO, 57.08 ± 17.87 pmol/mg) 
and, as normal thyroid, from control patients with multinodular goitre or thyroid cancer (156.71 ± 30.14 
pmol/mg) determined from quantitative Western blotting. The difference between GH and controls and GO and 
controls was highly significant (Mann-Whitney test p < 0.0001, p = 0.0012, respectively).  
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Figure 18. Correlation between mean (± standard error) CASQ1 protein levels and SNP rs3838216 genotype of 
the CASQ1 gene in patients with Graves’ hyperthyroidism (GH), which was significant (Mann-Whitney test, p = 
0.0223) for the homozygote genotype but not for the heterozygote genotype (Mann-Whitney test, p = ns).   
 
Enzyme-linked immunosorbent assay (ELISA) 
The presence and level of serum orbital antibodies in serum from patients whose thyroid 
tissue was used in the studies were determined using an enzyme-linked immunosorbent assay 
(ELISA). This procedure has been described in previous publications by this laboratory (5, 
12, 38) and it is standard. The antigen used was highly purified rabbit skeletal muscle CASQ1 
which shares 97% homology with human calsequestrin. Results were expressed as optical 
density (OD) at 405 nM.  A positive test was taken as an OD over the upper limit of the 
reference range, which was 194.   
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Figure 19. Levels of CASQ1 antibodies and protein antigen in GH and GO. There is clear significant differences 
between the antibody levels and protein antigen levels. Correlation between CASQ1 antibody levels determined 
by ELISA and CASQ1 protein concentration measured in quantitative western blot in patients with Graves’ 
hyperthyroidism  and Graves’ ophthalmopathy.   
 
Interestingly the presence of CASQ1 in thyroid is greater in controls than in patients with 
Graves’ disease. This suggests that the presence of the protein there in some way relates to the 
underlying autoimmune reaction, which, we believe precedes the orbit inflammatory process 
associated with Graves’ ophthalmopathy. 
Genotype analyses of 52 subjects have shown a correlation between the Control group and the 
patients with Graves’ Hyperthyroidism, linking the homozygote genotype to the disease.  
The 50kDa and 60kDa forms of the CASQ1 protein do not appear to be products of two 
different genes or alternative splicing. The 50 kDa may represent the unprocessed or post-
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translationally modified form of the mature protein. The 60 kDa form, the most abundant, 
appears to be the completely post-translationally modified protein.  
 
Discussion from Western Blot study 
The second part of the study involved the use of western blotting and density 
quantification allowing us to demonstrate that CASQ1 protein is present in the thyroid gland 
of patients with Graves’ disease and in controls’ thyroids, obtained from patients with cancer 
or multi nodular goitre. 
CASQ1 protein is present in smooth muscle cells as well as in other tissues. 
We showed the presence of two bands on the gel, at 50 kDa and at 60 kDa, in thyroid extract 
from both Graves’ patients and controls; both protein bands are the product of CASQ1 gene 
and do not appear to be the results of two different genes or alternate splicing. 
The two different molecular weights forms of CASQ1 protein may represent unprocessed and 
a mature form of the same protein; the 50 kDa may correspond to a CASQ1 protein that 
hasn’t undergone post-translational modifications. The 60 kDa form, the more abundant, 
appears to be the post-translationally modified form of the protein. 
Future use of immunofluorescence can determine where these two forms of CASQ1 protein 
are located, reaching the level of cellular organelles in the thyroid follicular cells and 
surrounding connective tissue. 
The results from this study showed that levels of the CASQ1 proteins were lower in 
Graves’ hyperthyroidism and Graves’ ophthalmopathy compared to controls.  
Further analyses from this study also took into account levels of CASQ1 protein in 5 patients 
with toxic nodular goitre and found that they weren’t significantly lower compared to those in 
control thyroid (p = 0.2663).  
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Genotype analyses of 52 subjects from this study were also linked to one polymorphism 
newly found in calsequestrin-1 gene.  
The results of this association showed a positive correlation between the reduced CASQ1 
levels and the homozygote genotype for the recently identified CASQ1 polymorphism 
rs3838216 (Lahooti, Cultrone, Wall et al, unpublished observations) (previously shown in 
Fig. 18) and between the absence of this polymorphism and serum titres of CASQ1 antibody. 
CASQ1 has been proven many times to be part of an ongoing process on the eye muscle 
component of Graves’ ophthalmopathy patient (4, 13, 46). 
The way CASQ1 works is not yet clear but speculations can be put together from our findings 
to try to elucidate and give shape to CASQ1’s role. A possible explanation to the reactions 
happening in the thyroid could be that the up regulation of the two forms of CASQ1 in the 
thyroid works as a trigger.  
This reaction, involving antibodies against CASQ1 protein and sensitized T-lymphocytes (6), 
then might spread to the orbit. It follows that, with the productions of the latter molecular 
actors targeting CASQ1, the concentration of the protein in thyroid will decrease, as seen in 
patients with Graves’ disease.  
Further studies will have to quantify CASQ1 protein concentration in many more toxic 
nodules in order to determine if there really is an autoimmune reaction or if it is due to 
Graves’ hyperthyroidism. If the toxic nodules show low levels of CASQ1 protein, like in the 
two cases analysed before the submission of this thesis, then it means that the reduction is due 
to hyperthyroidism. On the contrary, if the following analyses on more toxic nodules show the 
CASQ1 levels to be the same or higher, like in the one toxic nodule analysed after the 
submission of this thesis, then it means that an autoimmune process is going on. 
Another possible explanation to the reduction of CASQ1 protein in Graves’ disease is the 
shutting down of the translation of its mRNA. This mechanism could be a way for the 
68 
 
damaged cells to economize on unnecessary expenditure and to preserve the integrity of the 
cells caused by autoimmune reaction, although this is purely speculative.  
It seems likely that, in thyroid eye disease at least, the attack against the eye muscle 
component begins in the thyroid, with reaction against CASQ1, it then spreads to the eye 
muscles.  
Further studies from our research group unveiled an association between SNP rs3838216 and 
patients with severe eye disease. Patients with homozygous genotype (i.e. lacking the 
polymorphism on both alleles of the gene (DEL)) seem to have reduced CASQ1 protein levels 
as compared to control. Analysed data show high levels of CASQ1 antibody in Graves’ 
ophthalmopathy patients that have homozygous genotype (GO DEL) as compared to control 
group (CONTROL DEL). This increase in antibody levels, measured by ELISA technique, 
was not significant (p = 0.075). No statistical significance was found between CONTROL 
DEL and Graves’ hyperthyroidism homozygous group (GH DEL). 
In summary, results indicates that patients suffering from GO and GH with a 
homozygous genotype (absence of rs3838216 polymorphism), have reduced levels of CASQ1 
protein antigen measured by quantitative Western blot. However, in contrast to the reduction 
in protein levels, CASQ1 antibody levels increased in both GO and GH groups with 
homozygous genotype. Therefore, our results indicate that people who carry a homozygous 
genotype may have a propensity towards the development of the two forms of Graves’ 
disease, hyperthyroidism or ophthalmopathy. This particular genotype can be used as a risk 
factor marker aiming to the development of genetic test for GH and GO to confirm clinical 
observations in regards to particular subjects.  
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Chapter V: Conclusions and future 
directions 
 
Conclusions and future directions 
While there are other possibilities to explain this apparently contradictory finding our 
future studies will focus on the presumed link between the thyroid and orbital reactions and 
the role of CASQ1 in this context.  
The outcomes of this research studies adds more knowledge to the biological processes 
involved,  outlines more paths to follow, not only in terms of management and prevention of 
thyroid disease but also in therapeutic directions.  
Larger populations of patients and controls of different ethnic backgrounds might confirm the 
findings of SNP rs3838216 as genetic marker for Graves’ disease.  
Molecular genetic testing in larger samples, combined with autoantibody testing, could allow 
for the detection of other subjects ‘at risk’ of developing Graves’ disease, in its different 
forms and degrees.  
The results might also find other regions of the gene involved in the disease process, making 
possible the determination of phenotype-genotype correlations of CASQ1 to Graves’ disease. 
Testing on larger cohorts may add even more candidates within the pathways of Graves’ 
ophthalmopathy, which could give a better understanding of the paths from where to tackle 
the disorder. 
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This will result in a better direction of preventive therapy, if available in the future, or 
avoidance of negative environmental stimuli such as smoking (proven to be high risk factor 
also for this typology of disease (3)). 
At this stage there aren’t many clinical tests for ophthalmopathy other than the measurement 
of antibodies against calsequestrin and collagen XIII. This test has been found useful by 
ophthalmologists and endocrinologist to deal with various eye and thyroid disorders in their 
patients. 
Continuing on this research path might present new future management techniques for 
ophthalmopathy that are based on a simple genetic test capable of identify with what 
propensity a patient might develop ophthalmopathy. 
In regards to these speculations the future strategy might focus on creating a vector to be used 
in template cells and generate mutations in regions of interest on CASQ1 gene. Exploring the 
consequences of these controlled aberrations on CASQ1 protein structure and function will 
give us an insight into the processes involved, eventually re-addressing the focus of the 
research. In the longer term we may be able to prevent this distressful, frequently cosmetically 
disable, eye disorder.  
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